Roland Haubner1. 1. Universitätsklinik für Nuklearmedizin, Medizinische Universität Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. Roland.Haubner@uibk.ac.at
Abstract
OVERVIEW: The field of angiogenesis research is one of the most rapidly growing biomedical disciplines. Great efforts are being made to develop anti-angiogenesis drugs for treatment of cancer as well as non-oncological diseases. Thus, imaging techniques allowing non-invasive monitoring of corresponding molecular processes will be of great interest. One target structure involved in the angiogenic process is the integrin alphavbeta3, which mediates the migration of activated endothelial cells during vessel formation. MATERIALS AND METHODS: A variety of radiolabelled RGD peptides have been introduced for monitoring of alphavbeta3 expression using nuclear medicine tracer techniques. OBJECTIVES: This review discusses tracer development and highlights some strategies for tracer optimisation. It summarises the preclinical and clinical data and discusses the potential of this class of tracer to characterise angiogenesis.
OVERVIEW: The field of angiogenesis research is one of the most rapidly growing biomedical disciplines. Great efforts are being made to develop anti-angiogenesis drugs for treatment of cancer as well as non-oncological diseases. Thus, imaging techniques allowing non-invasive monitoring of corresponding molecular processes will be of great interest. One target structure involved in the angiogenic process is the integrin alphavbeta3, which mediates the migration of activated endothelial cells during vessel formation. MATERIALS AND METHODS: A variety of radiolabelled RGD peptides have been introduced for monitoring of alphavbeta3 expression using nuclear medicine tracer techniques. OBJECTIVES: This review discusses tracer development and highlights some strategies for tracer optimisation. It summarises the preclinical and clinical data and discusses the potential of this class of tracer to characterise angiogenesis.
Authors: R Haubner; H J Wester; U Reuning; R Senekowitsch-Schmidtke; B Diefenbach; H Kessler; G Stöcklin; M Schwaiger Journal: J Nucl Med Date: 1999-06 Impact factor: 10.057
Authors: P M van Hagen; W A Breeman; H F Bernard; M Schaar; C M Mooij; A Srinivasan; M A Schmidt; E P Krenning; M de Jong Journal: Int J Cancer Date: 2000-08-20 Impact factor: 7.396
Authors: Marcel Janssen; Wim J G Oyen; Leon F A G Massuger; Cathelijne Frielink; Ingrid Dijkgraaf; D Scott Edwards; Milind Radjopadhye; Frans H M Corstens; Otto C Boerman Journal: Cancer Biother Radiopharm Date: 2002-12 Impact factor: 3.099
Authors: Xiaoyuan Chen; Shuang Liu; Yingping Hou; Michel Tohme; Ryan Park; James R Bading; Peter S Conti Journal: Mol Imaging Biol Date: 2004 Sep-Oct Impact factor: 3.488
Authors: Stephanie N Histed; Maria L Lindenberg; Esther Mena; Baris Turkbey; Peter L Choyke; Karen A Kurdziel Journal: Nucl Med Commun Date: 2012-04 Impact factor: 1.690
Authors: John Kurhanewicz; Daniel B Vigneron; Kevin Brindle; Eduard Y Chekmenev; Arnaud Comment; Charles H Cunningham; Ralph J Deberardinis; Gary G Green; Martin O Leach; Sunder S Rajan; Rahim R Rizi; Brian D Ross; Warren S Warren; Craig R Malloy Journal: Neoplasia Date: 2011-02 Impact factor: 5.715
Authors: Ganapati H Mahabeleshwar; Juhua Chen; Weiyi Feng; Payaningal R Somanath; Olga V Razorenova; Tatiana V Byzova Journal: Cell Cycle Date: 2007-11-01 Impact factor: 4.534